Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb Computer Eye Drops with 1% glycerin due on shelves by Christmas.

This article was originally published in The Tan Sheet

Executive Summary

BAUSCH & LOMB COMPUTER EYE DROPS DUE ON SHELVES BY CHRISTMAS; shipments began in mid-November to food, drug and mass merchandisers, including Kmart and Wal-Mart. The eye drops, which contain 1% glycerin, are "specifically formulated to relieve, refresh, comfort, moisturize and revitalize tired, irritated, dry and stressed eyes," according to labeling. The product is targeted at sufferers of computer vision syndrome (CVS), an ailment "characterized by eye strain associated with prolonged computer use," the Rochester, N.Y.-based company said.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel